Efficacy of Phosphate Binding in Healthy Volunteers: Chewed Versus Crushed Lanthanum Carbonate

NCT ID: NCT00458289

Last Updated: 2019-12-20

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 12 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2007-01-31
• Study Completion Date: 2008-08-31

Brief Summary

Patients with end-stage renal disease (ESRD) commonly have high concentrations of phosphorous, a mineral, in the blood (hyperphosphatemia). This is a result of their inability to excrete phosphorous by the kidneys. This in turn may result in the development of a condition known as secondary hyperparathyroidism and renal osteodystrophy or bone disease. As such, these patients often receive medications known as phosphate binders such as calcium carbonate or acetate, sevelamer, aluminum hydroxide and lanthanum carbonate to manage and treat hyperphosphatemia.

Lanthanum carbonate is a newly available phosphate binding agent that is effective in the management of hyperphosphatemia and preventing secondary hyperparathyroidism. It works in the gastrointestinal tract by binding to the phosphorus in the diet. ESRD patients taking lanthanum carbonate are counseled to chew the tablets completely before swallowing, with or immediately after meals. However, patients who are intubated or receiving nutrition via feeding tubes are unable to chew the tablets. For these patients, medications are commonly crushed and administered via the tube. Moreover, some patients prefer to crush the tablets and mix it with food instead of chewing. To date, it is not known if crushing the lanthanum carbonate tablets prior to administration and taking it with food would be as effective as chewing them.

The purpose of this study is to compare the efficacy of phosphate binding between chewed and crushed lanthanum carbonate tablets.

Conditions

Hyperphosphatemia in Chronic Kidney Disease

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

1

P-containing meal alone

Group Type: NO_INTERVENTION

No interventions assigned to this group

2

P-containing meal AND single 1 g oral dose of chewed lanthanum carbonate

Group Type: ACTIVE_COMPARATOR

Lanthanum carbonate (chewed vs. crushed)

Intervention Type: DRUG

single 1 g oral dose of lanthanum carbonate either chewed or crushed into a fine powder

3

P-containing meal and single 1 g oral dose of lanthanum carbonate crushed into a fine powder

Group Type: ACTIVE_COMPARATOR

Lanthanum carbonate (chewed vs. crushed)

Intervention Type: DRUG

single 1 g oral dose of lanthanum carbonate either chewed or crushed into a fine powder

Interventions

Lanthanum carbonate (chewed vs. crushed)

single 1 g oral dose of lanthanum carbonate either chewed or crushed into a fine powder

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Men and women at least 18 years of age
• No clinically significant abnormal findings on clinical laboratory evaluation and medical history
• Within 15% of ideal body weight for height and build according to the Metropolitan Life tables5
• Women of child-bearing potential (premenopausal and not surgically sterilized) who have a negative pregnancy test
• Women who are sexually active must be using effective means of contraception

Exclusion Criteria

• History of dysphagia or swallowing disorders
• Clinically significant illness within 3 months of study enrollment
• Concomitant use of medication that might interact with lanthanum carbonate
• Pregnant or intends to become pregnant within 30 days of completing the study
• Breast feeding
• Alcohol or controlled substance abuse
• Use of an investigational agent within 30 days of study entry

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Shire

INDUSTRY

Sponsor Role: collaborator

University of Illinois at Chicago

OTHER

Sponsor Role: lead

Responsible Party

Alan Lau

Professor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Alan H Lau, Pharm.D.

Role: PRINCIPAL_INVESTIGATOR

University of Illinois at Chicago

Locations

University of Illinois at Chicago, Dept of Pharmacy Practice

Chicago, Illinois, United States

Countries

United States

Other Identifiers

2006-0530

Identifier Type: -

Identifier Source: org_study_id